Pei Huang1, Wei Hu1, Ying Zhu1, Yushen Wu2,3, Huapeng Lin1. 1. Department of Intensive Care Unit, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China. 2. Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 3. Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Abstract
BACKGROUND: Studies on the prognostic value of the soluble programmed death ligand 1 (sPD-L1) in cancer patients have not yielded consistent results. OBJECTIVE: This meta-analysis was performed to assess the association between sPD-L1 and the prognosis of cancer patients. METHODS: Published articles in Pubmed, EMBASE, and Cochrane clinical trial databases were searched from the inception to September 2020. Overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) data were evaluated using a hazard ratio (HR) at 95% confidence interval (95% CI). RESULTS: A total 31 studies involving 17 tumors and 3,780 patients were included. The overexpression of sPD-L1 was associated with shorter OS (HR 1.85, 95% CI 1.59-2.15, I2 = 33%). High sPD-L1 had worse PFS (HR 2.40, 95% CI 1.55-3.72, I2 = 83%), and worse DFS (HR 2.92, 95% CI 2.02-4.29, I2 = 40%), without significant statistical difference in RFS (HR 2.08, 95% CI 0.99-4.40, I2 = 0%). CONCLUSIONS: High sPD-L1 levels were associated with worse survival prognosis in cancer patients. The sPD-L1 may be a potential prognostic, non-invasive, and dynamic monitoring biomarker for cancers in the future.
BACKGROUND: Studies on the prognostic value of the soluble programmed death ligand 1 (sPD-L1) in cancer patients have not yielded consistent results. OBJECTIVE: This meta-analysis was performed to assess the association between sPD-L1 and the prognosis of cancer patients. METHODS: Published articles in Pubmed, EMBASE, and Cochrane clinical trial databases were searched from the inception to September 2020. Overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) data were evaluated using a hazard ratio (HR) at 95% confidence interval (95% CI). RESULTS: A total 31 studies involving 17 tumors and 3,780 patients were included. The overexpression of sPD-L1 was associated with shorter OS (HR 1.85, 95% CI 1.59-2.15, I2 = 33%). High sPD-L1 had worse PFS (HR 2.40, 95% CI 1.55-3.72, I2 = 83%), and worse DFS (HR 2.92, 95% CI 2.02-4.29, I2 = 40%), without significant statistical difference in RFS (HR 2.08, 95% CI 0.99-4.40, I2 = 0%). CONCLUSIONS: High sPD-L1 levels were associated with worse survival prognosis in cancer patients. The sPD-L1 may be a potential prognostic, non-invasive, and dynamic monitoring biomarker for cancers in the future.
Authors: Fabian Finkelmeier; Özge Canli; Andrea Tal; Thomas Pleli; Jörg Trojan; Michael Schmidt; Bernd Kronenberger; Stefan Zeuzem; Albrecht Piiper; Florian R Greten; Oliver Waidmann Journal: Eur J Cancer Date: 2016-03-31 Impact factor: 9.162
Authors: Paul Buderath; Esther Schwich; Christina Jensen; Peter A Horn; Rainer Kimmig; Sabine Kasimir-Bauer; Vera Rebmann Journal: Front Oncol Date: 2019-10-15 Impact factor: 6.244